Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $25,217 | $36,877 |
| General and administrative | 5,710 | 6,024 |
| Total operating expenses | 30,927 | 42,901 |
| Loss from operations | (30,927) | (42,901) |
| Other income (expense): | ||
| Interest expense | (3,509) | (2,689) |
| Interest income | 1,007 | 2,329 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s G&A?
- Inhibrx Biosciences, Inc. (INBX) reported G&A of $5.71M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s G&A changed year-over-year?
- Inhibrx Biosciences, Inc.'s G&A decreased by 5.2% year-over-year, from $6.02M to $5.71M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s G&A?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s G&A has grown at a -11.0% compound annual growth rate (CAGR), from $29.38M to $23.3M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Inhibrx Biosciences, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude